ESMO25 Breast Cancer Highlights: Antibody-Drug Conjugates | Dana-Farber Cancer Institute

20 Visioni
Published
Harold Burstein, MD, PhD, and Ilana Schlam, MD, MPH, discuss OptiTROP-Breast02 and other trials investigating antibody-drug conjugates (ADCs) presented at ESMO 2025.

For more information about Dana-Farber's Breast Oncology Center, visit https://www.dana-farber.org/cancer-care/treatment/breast-oncology
Categoria
Oncology
Commenta per primo questo video.